glatiramer acetate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
glatiramer acetate: clinical details
Prescribing considerations
- Initiation should be supervised by a neurologist or clinician experienced in multiple sclerosis.
- Ensure injection training, site rotation and recognition of post-injection reactions and anaphylaxis.
- Review cardiac, renal and hepatic history, alcohol intake and other potentially hepatotoxic medicines.
- Evidence is limited in older people, and paediatric safety and efficacy are not established.
Contraindications and cautions
- Hypersensitivity to glatiramer acetate or any formulation excipient.
- Do not administer intravenously or intramuscularly.
- Use caution and follow up patients with pre-existing cardiac disease.
Monitoring
- Monitor renal function in patients with renal impairment.
- Regularly assess for clinical features of hepatic injury; investigate promptly if symptoms occur.
- Review injection sites for lipoatrophy, persistent inflammation or necrosis.
- Reinforce the distinction between usually transient post-injection reactions and possible anaphylaxis.
Clinical pharmacology
A complex mixture of synthetic polypeptides containing four naturally occurring amino acids. It is thought to modulate innate immune cells and downstream B- and T-cell responses, increasing regulatory and anti-inflammatory cytokine activity; the precise therapeutic mechanism remains uncertain.
Formulation and product differences
- The selected product is a clear, single-use solution supplied in a pre-filled glass syringe.
- It contains mannitol and water for injections.
- The CSYNC autoinjector is specified for Copaxone pre-filled syringes and has not been tested with other pre-filled syringes.
- Keep refrigerated and protected from light; do not freeze. Temporary room-temperature storage is permitted once within the limits stated in the product information.
glatiramer acetate preparations and strengths
Injection
Route: Parenteral
Strengths: 20 mg/mL, 40 mg/mL
glatiramer acetate interactions
Formal interaction studies are limited, so the prescriber should review all medicines and supplements.
Phenytoin and carbamazepine
A theoretical protein-binding interaction means concurrent use should be monitored carefully, although displacement has not been demonstrated in laboratory studies.
Treatments commonly used in multiple sclerosis, including corticosteroids
Clinical and post-marketing experience has not identified a significant interaction, but evidence from formal interaction studies is limited.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.